Pharmasaga Co., Ltd.
TTPEX:7878143.00
TWD
-6.50
(-4.35%)
ISIN
TW0007878001
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Yue Chen Wu
- Full Time Employees
- 9
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- New Taipei Taiwan
- Website
- pharmasaga.com
- Similar Companies
- Business
- Pharmasaga Co., Ltd. is a Taiwan-based pharmaceutical and biotechnology company engaged in the research, development, manufacturing, and commercialization of specialty pharmaceuticals, active pharmaceutical ingredients (APIs), and advanced healthcare formulations. Founded in 2018 and headquartered in Taipei, Taiwan, the company operates across the biopharmaceutical, contract development, and healthcare sectors, serving institutional healthcare providers, pharmacy chains, and global life sciences partners across Taiwan, greater Asia-Pacific, and international markets. Pharmasaga structures its operations into three primary business divisions: Specialty Pharmaceuticals, Contract Development and Manufacturing Organization (CDMO) Services, and Consumer Healthcare Products. The company's core product and service portfolio comprises prescription pharmaceuticals and specialty therapeutics; complex generic formulations; active pharmaceutical ingredients (APIs) and customized chemical intermediates; oral solid dosage forms, including immediate- and modified-release tablets and capsules; sterile injectables and liquid dosage forms; end-to-end CDMO services encompassing formulation design, analytical method development, stability testing, and regulatory filing support; clinical trial supply manufacturing; and functional health supplements. The company distributes its therapeutic drug lines to medical centers, regional hospitals, clinics, and wholesale distribution networks, while delivering contract research and manufacturing services to multinational biotechnology and pharmaceutical enterprises. Pharmasaga maintains advanced laboratory and production facilities operating in accordance with current Good Manufacturing Practice (cGMP) and PIC/S GMP quality standards, supporting full-cycle development from molecular synthesis to scaled commercial manufacturing. In recent corporate developments, Pharmasaga has executed key strategic milestones to accelerate commercialization and broaden its operating footprint. The company completed its listing on the Taipei Exchange under the ticker 7878, strengthening its financial position to fund ongoing research programs and operational expansion. Pharmasaga has established strategic distribution alliances and licensing agreements with regional pharmaceutical partners to expand the commercial footprint of its therapeutic product lines across Asia-Pacific markets. In addition, the company recently completed capacity and technology upgrades across its manufacturing facilities, introduced advanced automated processing and quality control suites to expand its CDMO service bandwidth, and entered into collaborative research initiatives with biomedical institutions to advance novel formulation pipelines.